Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | CTSL | P07711 | 1/20 | 0.54 |
| ▸ | CTSB | P07858 | 1/20 | 0.54 |
| ▸ | CTSK | P43235 | 1/20 | 0.54 |
| ▸ | NAAA | Q02083 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2701945 | 0.98 | CTSL (0.53) | TSHRCTSLCTSBCTSKNAAA | |
| Hydrochloric Acid SCHEMBL30384626 | 0.96 | CTSL (0.51) | TSHRCTSLCTSBCTSKNAAA | |
| SCHEMBL6649338 | 0.96 | TSHR (0.54) | TSHRCTSLCTSBCTSKNAAA | |
| SCHEMBL17019782 | 0.92 | TSHR (0.58) | TSHRCTSLCTSBCTSKNAAA | |
| SCHEMBL1928095 | 0.92 | TSHR (0.58) | TSHRCTSLCTSBCTSKNAAA | |
| SCHEMBL23536377 | 0.88 | AGTR2 (0.47) | CTSLCTSBCTSK | |
| SCHEMBL6748142 | 0.85 | CTSL (0.51) | TSHRCTSLCTSBCTSKNAAA | |
| SCHEMBL2649981 | 0.84 | ALDH1A1 (0.45) | TSHRCTSLCTSBCTSKNAAA | |
| SCHEMBL2649979 | 0.84 | ALDH1A1 (0.45) | TSHRCTSLCTSBCTSKNAAA | |
| SCHEMBL17043168 | 0.83 | CTSL (0.50) | TSHRCTSLCTSBCTSKNAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220143231-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | JANSSEN BIOTECH, INC. | 2022-05-12 | — | — | US | disclosed |
| EP-3344613-B1 | HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS | DONG A SOCIO HOLDINGS CO LTD (KR) | 2020-03-04 | — | — | EP | disclosed |
| US-9850214-B2 | Inhibitors of NEDD8-activating enzyme | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| US-20170240944-A1 | Modified Cyanobacteria for Producing Carotenoids | Lumen Bioscience, Inc. | 2017-08-24 | — | — | US | disclosed |
| WO-2017039331-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2017-03-09 | — | — | WO | disclosed |
| EP-2433941-A1 | Process for isolating the antiviral agent [1S-(1alpha, 3alpha, 4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one | Bristol-Myers Squibb Company (US) | 2012-03-28 | — | — | EP | disclosed |
| EP-0945448-B1 | 5-ALKOXY-2(3H)-OXAZOLONE COMPOUNDS AND PROCESS FOR THE PREPARATION THEREOF | UBE INDUSTRIES (JP) | 2008-11-26 | — | — | EP | disclosed |
| US-6414160-B1 | REACTING 5-ALKOXY-2(3H)OXAZOLONE COMPOUND WITH ALDEHYDE COMPOUND IN PRESENCE OF LEWIS ACID CATALYST | UBE INDUSTRIES, LTD. (JP) | 2002-07-02 | — | — | US | disclosed |
| EP-1000937-A1 | PROCESS FOR PRODUCING 4-ALKOXYCARBONYL-2-OXAZOLIDINONE COMPOUNDS | UBE INDUSTRIES LIMITED (JP) | 2000-05-17 | — | — | EP | disclosed |
| US-6020496-A | 5-alkoxy-2(3H)-oxazolone compounds and process for preparing the same | UBE INDUSTRIES, LTD. (JP) | 2000-02-01 | — | — | US | disclosed |
| EP-0945448-A1 | 5-ALKOXY-2(3H)-OXAZOLONE COMPOUNDS AND PROCESS FOR THE PREPARATION THEREOF | UBE INDUSTRIES, LTD. (JP) | 1999-09-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220143231-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | BDNF, CD47, MAG | TSHR 1143/4885CTSL 612/4885CTSB 406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.